Scholarlink

<p>Pulmonary hypertension is a lethal condition characterized by an enhanced inflammatory response in the lungs. Cytokines such as interleukin-10 (IL-10) have demonstrated considerable potential as potent inflammation suppressors. Especially, with pulmonary hypertension patients showing diminished IL-10 levels. However, off-target toxicity poses a major limitation to their applications. Here we report a strategy in which IL-10 mRNA, encapsulated in extracellular vesicles, is delivered by inhalation. Targeted delivery to lung with preferential uptake reduces systemic side effects. IL-10 mRNA exerts selective immunomodulatory effects by suppressing inflammatory cytokine secretion and promoting apoptosis in M1-like pulmonary macrophages while sparing M2-like macrophages. This macrophage subset-specific regulation reshapes the pulmonary cytokine microenvironment, significantly down-regulating factors that promote pulmonary hypertension progression and ultimately inhibiting disease progression. The strategy was demonstrated in the sugen5416/hypoxia-induced rat model of pulmonary hypertension, providing substantial protection against disease progression. This shows the potential for locally delivered cytokine-based immunosuppressive therapies for inflammatory lung diseases.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhalable extracellular vesicle delivered IL-10 mRNA attenuates pulmonary hypertension in rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月23日

查看全文
  • Guoliang Wang,
  • Jie Liu,
  • Peiyi Bai,
  • Hong Jiao,
  • Xiaohui Kong,
  • Zhangke Guo,
  • Gaopeng Li,
  • Aijun Liu

摘要

Pulmonary hypertension is a lethal condition characterized by an enhanced inflammatory response in the lungs. Cytokines such as interleukin-10 (IL-10) have demonstrated considerable potential as potent inflammation suppressors. Especially, with pulmonary hypertension patients showing diminished IL-10 levels. However, off-target toxicity poses a major limitation to their applications. Here we report a strategy in which IL-10 mRNA, encapsulated in extracellular vesicles, is delivered by inhalation. Targeted delivery to lung with preferential uptake reduces systemic side effects. IL-10 mRNA exerts selective immunomodulatory effects by suppressing inflammatory cytokine secretion and promoting apoptosis in M1-like pulmonary macrophages while sparing M2-like macrophages. This macrophage subset-specific regulation reshapes the pulmonary cytokine microenvironment, significantly down-regulating factors that promote pulmonary hypertension progression and ultimately inhibiting disease progression. The strategy was demonstrated in the sugen5416/hypoxia-induced rat model of pulmonary hypertension, providing substantial protection against disease progression. This shows the potential for locally delivered cytokine-based immunosuppressive therapies for inflammatory lung diseases.

Graphical Abstract